Interest of Youth Living With HIV in Long-Acting Antiretrovirals

Ethel Weld, Md Sohel Rana, Ronald H. Dallas, Andres F. Camacho-Gonzalez, Patrick Ryscavage, Aditya H. Gaur, Rana Chakraborty, Susan Swindells, Charles Williams Flexner, Allison Lorna Agwu

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: This study's primary objective was to characterize attitudes to long-acting antiretrovirals (LAARV), among youth aged 13-24 years living with perinatally acquired HIV and nonperinatally acquired HIV. Secondary objectives included: assessing whether those with detectable HIV RNA PCR viral load had higher enthusiasm for LAARV compared to those with suppressed viral load, and examining characteristics associated with LAARV enthusiasm. METHODS: A cross-sectional survey of 303 youth living with HIV (YHIV) followed at 4 pediatric/adolescent HIV clinics in the United States was performed to determine interest in LAARV, using a modified survey instrument previously used in adults. Interest in LAARV across groups was compared. Poisson regression with robust variance was used to determine the impact of various characteristics on interest in LAARV. FINDINGS: Overall, 88% of YHIV reported probable or definite willingness to use LAARV. The enthusiasm level was similar between youth with perinatally acquired HIV and nonperinatally acquired HIV (P = 0.93). Youth with HIV viral load >1000 copies per milliliter had significantly higher interest than youth with suppressed viral load [prevalence ratio 1.12 (95% confidence interval: 1.03 to 1.20); P = 0.005]. Female youth participants who had had past experience with implantable contraceptive methods had a significantly higher interest in LAARV (100% vs. 85.5%; P = 0.002). Proportion of respondents endorsing definite willingness to use was significantly higher with decreased injection frequency compared with increased injection frequency. INTERPRETATION: YHIV at 4 urban US pediatric/adolescent HIV clinics had high levels of enthusiasm for LAARV. LAARV should be given high priority as a potentially viable treatment option to improve clinical outcomes in YHIV.

Original languageEnglish (US)
Pages (from-to)190-197
Number of pages8
JournalJournal of acquired immune deficiency syndromes (1999)
Volume80
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

HIV
Viral Load
Pediatrics
Injections
Contraception
Cross-Sectional Studies
RNA
Confidence Intervals
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Interest of Youth Living With HIV in Long-Acting Antiretrovirals. / Weld, Ethel; Rana, Md Sohel; Dallas, Ronald H.; Camacho-Gonzalez, Andres F.; Ryscavage, Patrick; Gaur, Aditya H.; Chakraborty, Rana; Swindells, Susan; Flexner, Charles Williams; Agwu, Allison Lorna.

In: Journal of acquired immune deficiency syndromes (1999), Vol. 80, No. 2, 01.02.2019, p. 190-197.

Research output: Contribution to journalArticle

Weld, E, Rana, MS, Dallas, RH, Camacho-Gonzalez, AF, Ryscavage, P, Gaur, AH, Chakraborty, R, Swindells, S, Flexner, CW & Agwu, AL 2019, 'Interest of Youth Living With HIV in Long-Acting Antiretrovirals', Journal of acquired immune deficiency syndromes (1999), vol. 80, no. 2, pp. 190-197. https://doi.org/10.1097/QAI.0000000000001896
Weld, Ethel ; Rana, Md Sohel ; Dallas, Ronald H. ; Camacho-Gonzalez, Andres F. ; Ryscavage, Patrick ; Gaur, Aditya H. ; Chakraborty, Rana ; Swindells, Susan ; Flexner, Charles Williams ; Agwu, Allison Lorna. / Interest of Youth Living With HIV in Long-Acting Antiretrovirals. In: Journal of acquired immune deficiency syndromes (1999). 2019 ; Vol. 80, No. 2. pp. 190-197.
@article{2be66d0bf95b4e4c88367922a0aef8e7,
title = "Interest of Youth Living With HIV in Long-Acting Antiretrovirals",
abstract = "OBJECTIVES: This study's primary objective was to characterize attitudes to long-acting antiretrovirals (LAARV), among youth aged 13-24 years living with perinatally acquired HIV and nonperinatally acquired HIV. Secondary objectives included: assessing whether those with detectable HIV RNA PCR viral load had higher enthusiasm for LAARV compared to those with suppressed viral load, and examining characteristics associated with LAARV enthusiasm. METHODS: A cross-sectional survey of 303 youth living with HIV (YHIV) followed at 4 pediatric/adolescent HIV clinics in the United States was performed to determine interest in LAARV, using a modified survey instrument previously used in adults. Interest in LAARV across groups was compared. Poisson regression with robust variance was used to determine the impact of various characteristics on interest in LAARV. FINDINGS: Overall, 88{\%} of YHIV reported probable or definite willingness to use LAARV. The enthusiasm level was similar between youth with perinatally acquired HIV and nonperinatally acquired HIV (P = 0.93). Youth with HIV viral load >1000 copies per milliliter had significantly higher interest than youth with suppressed viral load [prevalence ratio 1.12 (95{\%} confidence interval: 1.03 to 1.20); P = 0.005]. Female youth participants who had had past experience with implantable contraceptive methods had a significantly higher interest in LAARV (100{\%} vs. 85.5{\%}; P = 0.002). Proportion of respondents endorsing definite willingness to use was significantly higher with decreased injection frequency compared with increased injection frequency. INTERPRETATION: YHIV at 4 urban US pediatric/adolescent HIV clinics had high levels of enthusiasm for LAARV. LAARV should be given high priority as a potentially viable treatment option to improve clinical outcomes in YHIV.",
author = "Ethel Weld and Rana, {Md Sohel} and Dallas, {Ronald H.} and Camacho-Gonzalez, {Andres F.} and Patrick Ryscavage and Gaur, {Aditya H.} and Rana Chakraborty and Susan Swindells and Flexner, {Charles Williams} and Agwu, {Allison Lorna}",
year = "2019",
month = "2",
day = "1",
doi = "10.1097/QAI.0000000000001896",
language = "English (US)",
volume = "80",
pages = "190--197",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Interest of Youth Living With HIV in Long-Acting Antiretrovirals

AU - Weld, Ethel

AU - Rana, Md Sohel

AU - Dallas, Ronald H.

AU - Camacho-Gonzalez, Andres F.

AU - Ryscavage, Patrick

AU - Gaur, Aditya H.

AU - Chakraborty, Rana

AU - Swindells, Susan

AU - Flexner, Charles Williams

AU - Agwu, Allison Lorna

PY - 2019/2/1

Y1 - 2019/2/1

N2 - OBJECTIVES: This study's primary objective was to characterize attitudes to long-acting antiretrovirals (LAARV), among youth aged 13-24 years living with perinatally acquired HIV and nonperinatally acquired HIV. Secondary objectives included: assessing whether those with detectable HIV RNA PCR viral load had higher enthusiasm for LAARV compared to those with suppressed viral load, and examining characteristics associated with LAARV enthusiasm. METHODS: A cross-sectional survey of 303 youth living with HIV (YHIV) followed at 4 pediatric/adolescent HIV clinics in the United States was performed to determine interest in LAARV, using a modified survey instrument previously used in adults. Interest in LAARV across groups was compared. Poisson regression with robust variance was used to determine the impact of various characteristics on interest in LAARV. FINDINGS: Overall, 88% of YHIV reported probable or definite willingness to use LAARV. The enthusiasm level was similar between youth with perinatally acquired HIV and nonperinatally acquired HIV (P = 0.93). Youth with HIV viral load >1000 copies per milliliter had significantly higher interest than youth with suppressed viral load [prevalence ratio 1.12 (95% confidence interval: 1.03 to 1.20); P = 0.005]. Female youth participants who had had past experience with implantable contraceptive methods had a significantly higher interest in LAARV (100% vs. 85.5%; P = 0.002). Proportion of respondents endorsing definite willingness to use was significantly higher with decreased injection frequency compared with increased injection frequency. INTERPRETATION: YHIV at 4 urban US pediatric/adolescent HIV clinics had high levels of enthusiasm for LAARV. LAARV should be given high priority as a potentially viable treatment option to improve clinical outcomes in YHIV.

AB - OBJECTIVES: This study's primary objective was to characterize attitudes to long-acting antiretrovirals (LAARV), among youth aged 13-24 years living with perinatally acquired HIV and nonperinatally acquired HIV. Secondary objectives included: assessing whether those with detectable HIV RNA PCR viral load had higher enthusiasm for LAARV compared to those with suppressed viral load, and examining characteristics associated with LAARV enthusiasm. METHODS: A cross-sectional survey of 303 youth living with HIV (YHIV) followed at 4 pediatric/adolescent HIV clinics in the United States was performed to determine interest in LAARV, using a modified survey instrument previously used in adults. Interest in LAARV across groups was compared. Poisson regression with robust variance was used to determine the impact of various characteristics on interest in LAARV. FINDINGS: Overall, 88% of YHIV reported probable or definite willingness to use LAARV. The enthusiasm level was similar between youth with perinatally acquired HIV and nonperinatally acquired HIV (P = 0.93). Youth with HIV viral load >1000 copies per milliliter had significantly higher interest than youth with suppressed viral load [prevalence ratio 1.12 (95% confidence interval: 1.03 to 1.20); P = 0.005]. Female youth participants who had had past experience with implantable contraceptive methods had a significantly higher interest in LAARV (100% vs. 85.5%; P = 0.002). Proportion of respondents endorsing definite willingness to use was significantly higher with decreased injection frequency compared with increased injection frequency. INTERPRETATION: YHIV at 4 urban US pediatric/adolescent HIV clinics had high levels of enthusiasm for LAARV. LAARV should be given high priority as a potentially viable treatment option to improve clinical outcomes in YHIV.

UR - http://www.scopus.com/inward/record.url?scp=85059879538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059879538&partnerID=8YFLogxK

U2 - 10.1097/QAI.0000000000001896

DO - 10.1097/QAI.0000000000001896

M3 - Article

C2 - 30418298

AN - SCOPUS:85059879538

VL - 80

SP - 190

EP - 197

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 2

ER -